Lecanemab-irmb - Uses and Side Effects

What Is Lecanemab-irmb?

Lecanemab-irmb is a medicine used to treat Alzheimer’s disease. It is given through a drip into a vein (intravenous injection). This medicine helps slow down the worsening of the disease and reduces the chances of symptoms getting worse over time. It has shown good results in patients with Alzheimer’s disease.

Is Lecanemab-irmb FDA-approved?

It was approved by the Food and Drug Administration on January 6, 2023.

How Does Lecanemab-irmb Work?

In Alzheimer’s disease, sticky protein deposits called amyloid plaques build up in the brain. These harmful plaques damage brain cells and interfere with memory and thinking. Lecanemab-irmb acts by targeting and reducing these plaques. By lowering the amount of amyloid in the brain, the medicine helps slow down further damage to brain cells.

Uses:

Lecanemab-irmb is used to treat early Alzheimer’s disease, including people with mild memory problems or early dementia. It lowers a substance called amyloid beta, which usually builds up in the brain in Alzheimer’s disease.

It is important to understand that this medicine is not a cure, but it may help slow the worsening of memory loss and daily functioning.

Dosage:

This medicine is given only through a vein (intravenous injection). It is not available as tablets or capsules.

• 200 milligram/2 milliliter single-dose vial.

• 500 mg/2 ml single-dose vial.

Before giving the injection, the medicine must be diluted properly. Doctors also need to confirm that the amyloid protein is present in the brain before starting treatment.

Warnings

While administering the drug, there is a chance an individual may experience symptoms of an infusion reaction. Some of them are mentioned below:

• Shortness of breath.

• Fever.

• Chills.

• Joint pain.

• Nausea.

• Vomiting.

• Tiredness.

• Fatigue.

For Patients

When and How Often to Take Lecanemab-irmb?

The drug is given through an IV every two weeks. It is usually administered in a hospital by a healthcare professional. Patients are closely monitored to ensure safety and avoid side effects.

How Effective Is Lecanemab-irmb?

The drug has exhibited a statistically significant reduction in brain amyloid levels. It slows down the disease progression and has proven better efficacy in treating the condition.

Things to Inform the Doctor Before They Prescribe Lecanemab-irmb:

Before the doctor prescribes the drug, it is best to inform them of any previous history of allergies. In addition, informing about the medical and drug history can help the doctor administer the drug or consider altering the dose to prevent any unwanted drug interactions.

How to Take Lecanemab-irmb?

Lecanemab-irmb is given through a vein (IV drip) once every two weeks. It is usually given in a hospital or clinic, where doctors and nurses can watch the patient closely. Regular monitoring is important to make sure the treatment is safe and to quickly manage any side effects.

Things to Do Before Starting Taking Lecanemab-irmb:

Before starting treatment, the patient or caregiver should inform the doctor about:

• Any past allergies.

• All medical conditions.

• Any medicines currently being taken.

This helps the doctor decide if the drug is safe and whether any dose changes are needed to avoid side effects or drug interactions.

Side Effects

The drug may cause swelling of the brain and could have small bleeding spots on the brain surface. So the doctor may perform magnetic resonance imaging before and after treatment to watch out for side effects.

Some additional side effects of the drug are mentioned below:

• Difficulty in breathing.

• Swelling in the face.

• Headache.

• Confusion.

• Dizziness.

• Nausea.

• Difficult walking.

• Seizures.

• Allergic reactions.

Dietary Alterations:

No special diet is needed while taking this medicine. Eating normal, healthy, balanced food is enough, unless your doctor or dietitian advises otherwise.

What Should Be Done When a Dose Is Missed?

If a dose is missed, inform the doctor as soon as possible. Missing doses often can reduce the benefit of the treatment and may worsen the condition.

What Should Be Done to Treat Lecanemab-irmb Overdose?

If too much medicine is given, seek medical help immediately. Doctors will monitor vital signs such as blood pressure and heart rate and provide treatment as needed.

How to Store Lecanemab-irmb?

• Store at room temperature.

• Do not freeze.

• Keep away from children and pets.

• Dispose of needles safely to avoid injuries.

How to Handle Lecanemab-irmb?

The medicine should be handled carefully by trained staff. Sterile needles are used to prevent infection. The injection site is cleaned, and the medicine is given slowly through a vein over about one hour.

How to Dispose of Lecanemab-irmb?

Unused or expired medicine should be disposed of as advised by the manufacturer or through approved medicine take-back programs. Do not throw it in regular household waste.

Avoid Self-Medication:

Self-medication can cause unwanted adverse effects. So it is always better to take medications under the supervision of healthcare professionals.

Staying On Lecanemab-irmb:-

It is important to take the drug at the same time every day. So it is important to keep reminders to take the medication promptly for better recovery.

For Doctors

Indication:

The drug is used in patients suffering from Alzheimer’s disease. The drug does not completely cure the condition but helps improve the disease's symptoms and prevents further progression. So it is preferably used in mild or moderate dementia for better results.

Pharmacology

Mechanism of Action:

The drug is a monoclonal antibody that is directed towards soluble and insoluble forms of the amyloid protein. The drug targets the soluble oligomers and insoluble fibrils. As the drug is a humanized immunoglobulin gamma 1, it helps to get rid of the amyloid beta plaques in the brain, which defines the pathophysiological feature of Alzheimer’s disease.

Ingredients:

Active Ingredient: Lecanemab-irmb.

Inactive Ingredients:

• Methylcellulose.

• Sterile water.

Absorption:

The drug is absorbed rapidly into the bloodstream as it is administered intravenously. The absorption is quick and rapid. The steady-state concentration of the drug is reached in approximately six weeks when the drug is administered every two weeks.

Systemic accumulation of the drug was observed to be one to fourfold. The plasma concentration of the drug increases proportionally to the dose after a single dose.

Distribution:

The mean volume of drug distribution is about 0.85 US gallons. It is degraded by proteolytic enzymes.

Metabolism and Elimination:

The drug is degraded by proteolytic enzymes, which help to undergo complete metabolism. The half-life of the drug is about five to seven days. The drug is not expected to undergo any elimination via the kidneys or hepatic enzymes. If there is any incidence of anti-drug antibodies, it is highly dependent on the sensitivity and specificity of the assay.

Toxicity

The drug can cause severe risks like brain swelling and bleeding. In addition, it could also lead to hypersensitivity reactions like angioedema, bronchospasm, and anaphylaxis. In such cases, the drug should be discontinued if there are any such reactions, and appropriate therapy should be initiated.

Administration of the Drug:

The drug is administered via the intravenous route once every two weeks. Each intravenous injection lasts for approximately one hour for every infusion. This drug administration is usually performed in hospitals under the supervision of healthcare professionals.

Contraindications

• This medicine should not be used in children.

• It should also be avoided during breastfeeding, as its safety is not clearly known.

Clinical Studies for Lecanemab-irmb

In a large study of 1,795 people aged 50 to 90 years with early Alzheimer’s disease, patients received the medicine every two weeks. The results showed that the medicine slowed the worsening of the disease and helped reduce symptoms in many patients.

Drug Interactions:

This medicine does not commonly interact with other drugs. However, telling the doctor about all medicines being taken is important to avoid side effects.

Other Specifications

Lecanemab-irmb in Pregnant Women:

There is not enough information about safety during pregnancy. Doctors will weigh the risks and benefits before considering its use.

Lecanemab-irmb in Lactating Women:

It is unclear if the medicine passes into breast milk. Because of possible risks to the baby, it is usually avoided.

Lecanemab-irmb in Pediatric Patients:

This medicine is not meant for children. Alzheimer’s disease is very rare in this age group, and safety has not been established.

Lecanemab-irmb in Geriatric Patients:

The drug is used in geriatric patients who suffer from Alzheimer’s disease. But before administering the drug, it is important to look for comorbidities. Also, in some patients, dosage alteration may be required.

Lecanemab-irmb in Renal Impairment Patients:

The usage of the drug in renal-impaired patients is under study. So it is safer to avoid the drug in renal-impaired patients. The medical professional will decide the need for drug usage based on the severity of the disease and alter the dosage as required.

Lecanemab-irmb in Hepatic Impairment Patients:

Use in liver disease is not well understood. Close monitoring is needed, and dose changes may be required in some patients.